Tardive and spontaneous dyskinesia incidence in the general population

BMC Psychiatry

Volumn 13, Issue , 2013, Pages

  Merrill, Ray M ^a   Lyon, Joseph L ^b   Matiaco, Paul M ^a  

^a BRIGHAM YOUNG UNIVERSITY   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotic drugs; Dyskinesia; Incidence rates; Metoclopramide; Risk factors

Indexed keywords

METOCLOPRAMIDE; NEUROLEPTIC AGENT;

ARTICLE; BLEPHAROSPASM; CLINICAL ARTICLE; DIABETES MELLITUS; DRUG EXPOSURE; EYELID MUSCLE; FEMALE; HUMAN; INCIDENCE; MALE; MEDICAL RECORD REVIEW; POPULATION; PSYCHOSIS; RETROSPECTIVE STUDY; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ADULT; ANTIPSYCHOTIC AGENTS; DYSKINESIA, DRUG-INDUCED; DYSKINESIAS; FEMALE; HUMANS; INCIDENCE; MALE; METOCLOPRAMIDE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SCHIZOPHRENIA; SEX FACTORS; UNITED STATES;

EID: 84878221886     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-13-152     Document Type: Article

References (39)

1. Stedman JK. Stedman's medical dictionary for the health professions and nursing 2005, Baltimore, MD: Lippincott Williams & Wilkins.
2. Loonen AJ, Ivanova SA. New insights into the mechanism of drug-induced dyskinesia. CNS Spectr 2013, 18(1):15-20. 10.1017/S1092852912000752, 23593652.
3. Glazer GM. Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J Clin Psychiatry 2000, 61(4):15-20.
4. Morganstern M, Glazer WM, Niedzwiecki D, Nouriah P. The impact of neuroleptic medication on tardive dyskinesia: a meta-analysis of published studies. AJPH 1987, 77(6):717-724.
5. Tenback DE, van Harten PN, Slooff CJ, Belger MA, van Os J, SOHO Study Group Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. J Clin Psychiatry 2005, 66(9):1130-1133. 10.4088/JCP.v66n0907, 16187770, SOHO Study Group.
6. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008, 21(2):151-156. 10.1097/YCO.0b013e3282f53132, 18332662.
7. Keltner NL, Folks DG. Psychotropic Drugs 2005, Maryland Heights, MO: Elsevier Mosby, 4.
8. Gervin M, Browne S, Lane A, Clarke M, Waddington JL, Larkin C, O'Callaghan E. Spontaneous abnormal involuntary movements in first-episode schizophrenia and schizophreniform disorder: baseline rate in a group of patients from an Irish catchment area. Am J Psychiatry 1998, 155(9):1202-1206.
9. McCreadie RG, Padmavati R, Thara R, Srinivasan TN. Spontaneous dyskinesia and parkinsonism in never-medicated, chronically ill patients with schizophrenia: 18-month follow-up. Br J Psychiatry 2002, 181:135-137.
10. Fenton WS, Wyatt RJ, McGlashan TH. Risk factors for spontaneous dyskinesia in schizophrenia. Arch Gen Psychiatry 1994, 51(8):643-650. 10.1001/archpsyc.1994.03950080055008, 8042913.
11. Wiholm BE, Mortimer T, Boethius G, Häggström JE. Tardive dyskinesia associated with Metoclopramide. BMJ 1984, 288(6416):545-547. 10.1136/bmj.288.6416.545, 1444584, 6421373.
12. Ganzini L, Casey DE, Hoffman WF, McCall AL. The prevalence of metoclopramide-induced Tardive Dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med 1993, 153:1469-1475. 10.1001/archinte.1993.00410120051007, 8512437.
13. Smith JM, Baldessarini RJ. Changes in prevalence, severity and recovery in tardive diskinesia with age. Arch Gen Psychiatry 1980, 37:1368-1373. 10.1001/archpsyc.1980.01780250054006, 6108750.
14. Inada T, Ohnishi K, Kamisada M, Matsuga G, Tajima O, Hashiguchi K, Shima S, Oh-e Y, Masuda Y. A prospective study of tardive diskinesia in Japan. Eur Arch Psychiatry Clin Neurosci 1991, 240(4-5):250-254.
15. Woerner MG, Saltz BL, Kane JM, Lieberman JA, Alvir JMJ. Diabetes and development of tardive diskinesia. Am J Psychiatry 1993, 150:966-968.
16. Ganzini L, Heintz RT, Hoffman WF, Casey DE. The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study. Arch Gen Psychiatry 1991, 48(3):259-263. 10.1001/archpsyc.1991.01810270071010, 1671743.
17. Raja M, Azzoni A. Diabetes is not a risk factor for tardive dyskinesia. A retrospective observational study. Hum Psychopharmacol Clin Exp 2001, 17:61-63.
18. Pasricha JP, Pelivanov N, Sugumar A, Jankovic J. Drug insight: from disturbed motility to disordered movement- a review of the clinical benefits and medicological risks of metoclopramide. Nature 2006, 3(3):138-148.
19. Tang DM, Friedenberg FK. Gastroparesis: approach, diagnostic evaluation, and management. Dis Mon 2011, 57(2):74-101. 10.1016/j.disamonth.2010.12.007, 21329779.
20. Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician 2010, 81(5):617-622.
21. Sweet RA, Mulsant BH, Rifai AH, Zubenko GS. Dyskinesia and neuroleptic exposure in elderly psychiatric inpatients. J Geriatr Psychiatry Neurol 1992, 5(3):156-161.
22. Yassa R, Nastase C, Dupont D, Thibeau M. Tardive dyskinesia in elderly psychiatric patients: a 5-year study. Am J Psychiatry 1992, 149(9):1206-1211.
23. Merrill RM, Lyon JL, Baker RK, Gren LH. Attention deficit hyperactivity disorder and increased risk of injury. Adv Med Sci 2009, 54(1):20-26.
24. Merrill RM, Lindsay GB, Lyon JL. Tobacco-related cancers in the Utah compared to the United States: Quantifying the benefits of the Word of Wisdom. BYU Studies 1999, 38(4):91-105.
25. ICD-9-CM International Classification of Diseases, 9th Revision; Clinical Modification 2006, Los Angeles, CA: PMIC, 7, ICD-9-CM.
26. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982, 39:486.
27. Stringer J. Basic Concepts in Pharmacology: What You Need to Know for Each Drug Class 2011, New York, NY: McGraw-Hill Companies Inc., 4.
28. Alan FS, Nemeroff CB. The American Psychiatric Publishing Textbook of Psychopharmacology 2009, Arlington, VA: American Psychiatric Publishing, 4.
29. Jeste DV, Lacro JP, Palmer B, Rockwell E, Harris MJ, Caligiuri MP. Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients. Am J Psychiatry 1999, 156(2):309-311.
30. FDA News Release FDA requires boxed warning and risk mitigation strategy for Metoclopramide containing drugs: Agency warns against chronic use of these products to treat gastrointestinal disorders 2009, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm149533.htm, FDA News Release.
31. Blanes C, Colom H, Moreno J, Obach R, Peraire C, Domenech J. Comparative study " in vitro" of transdermal absorption of a series of antiemetic drugs. Eur J Drug Metab Pharmacokinet 1991, 3:410-414.
32. Calpena AC, Blanes C, Moreno J, Obach R, Domenech J. A comparative in vitro study of transdermal absorption of antiemetics. J Pharm Sci 1994, 83(1):29-33. 10.1002/jps.2600830108, 8138905.
33. Pappa S, Dazzan P. Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review. Psychol Med 2009, 39:1065-1076. 10.1017/S0033291708004716, 19000340.
34. Lee J, Poon L, Chong S. Spontaneous dyskinesia in first-episode psychosis in a Southeast Asian population. J Clin Psychopharmacol 2008, 28:536-539. 10.1097/JCP.0b013e3181845f59, 18794649.
35. Bateman DN, Rawlins MD, Simpson JN. Extrapyramidal reactions with metoclopramide. Brit Med J 1985, 291:930-932.
36. Glazer WM, Morgenstern H, Doucette JT. Predicting long term risk of tardive dyskinesia in outpatients maintained on neuroleptic medication. J Clin Psychiatry 1993, 54:133-139.
37. Nilsson A, Waller L, Rosengren A, Adlerberth A, Wilhelmsen L. Cigarette smoking is associated with abnormal involuntary movements in the general male population-a study of men born in 1933. Biol Psychiatry 1997, 41(6):717-723. 10.1016/S0006-3223(96)00289-2, 9066996.
38. Chong SA, Tan EC, Tan CH. Smoking and tardive dyskinesia: lack of involvement of the CYP1A2 gene. J Psychiatry Neurosci 2003, 28(3):185-189. 161742, 12790158.
39. Sewell DD, Kodsi AB, Caligiuri MP, Jeste DV. Metoclopramide and tardive dyskinesia. Biol Psychiatry 1994, 36:630-632. 10.1016/0006-3223(94)90077-9, 7833431.